فهرست نشریات علمی دسترسی آزاد ایران

Background and Aim: Examining the evolution of drug protection practices from the pre-modern to the post-modern era, dating back to 3000 BC, is essential to gain a comprehensive understanding of trends, historical patterns and evidence-based strategies for addressing the problem of counterfeit drugs in the modern era. Tracing this evolutionary path provides valuable insights into the historical context, challenges and advances made in combating the illicit production and distribution of counterfeit drugs. This paper traces the historical trajectory of efforts to protect pharmaceutical products against counterfeiting over time and outlines key historical developments, innovations and regulatory frameworks that have shaped the landscape of drug safety and anti-counterfeiting efforts. Methods: This research, using an analytical-descriptive and quantitative coursework method, based on reliable documentation and archival sources, including domestic and foreign books and articles, has examined the status of the protection of pharmaceutical products and how its laws and regulations have evolved over the period from 3000 BC to 2024 by searching for the keywords laws, drug protection, public health, counterfeiting, ancient, modern and postmodern in the electronic scientific database Google Scholar. Ethical Considerations: In this study, ethical considerations, honesty and trustworthiness have been observed in referencing texts to the sources. Results: The evolution of legal measures to protect pharmaceutical products shows the transition from primitive customary laws to formal frameworks in the modern era. The introduction of pharmacopoeias and consumer protection laws marked significant advances in regulating the drug quality and authenticity. Legal and ethical approaches to protect pharmaceutical products have evolved significantly from the pre-modern to the post-modern era, accompanied by technological advances. Conclusion: Inspired by historical developments and adapting to new challenges, it emphasizes the need for continued vigilance and the development of innovation and new technologies in protecting public health and ensuring the safety and efficacy of pharmaceutical products. It is essential to shift regulatory strategies related to regulatory practices from a reactive approach to a proactive and practical stance focused on prevention.